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Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction characterized by necrosis of the
epidermis. Its incidence is approximately 1 per million a year and average mortality rate is high at 25
e50%. TEN has a ﬂu-like prodrome, followed by atypical, targetoid erythematous or purpuric macules on
the skin. These macules coalesce to form ﬂaccid blisters that slough off as areas of epidermal necrosis.
Drugs such as allopurinol, sulfonamides, and carbamazepine are the most common causes. The human
leukocyte antigen (HLA)-B*15:02 in Asians being administered carbamazepine and the HLA-B*58:01
antigen in patients of all ethnicities being administered allopurinol are known to be high-risk factors.
Rapid diagnosis, discontinuation of the causative drug, and supportive treatment are essential for better
prognosis and improvement of sequelae. Till now, systemic corticosteroids and intravenous immuno-
globulins have been used as the most common active interventions; however, no gold standard has been
established. In Japan, physicians follow a unique diagnostic criteria and treatment guideline to improve
the diagnosis rate and streamline treatments. This may be a contributing factor for the lower mortality
rate (14.3%). The efﬁcacy of systemic corticosteroids, immunoglobulins, and plasmapheresis may have
been beneﬁcial as well. In Japan, TEN is deﬁned as an epidermal detachment of over 10% of the body
surface area (BSA), while the globally accepted deﬁnition established by Bastuji-Garin describes it as an
epidermal detachment of over 30% of the BSA. In Japanese individuals, HLA-A*02:06, HLA-A*02:07, HLA-
A*31:01 and HLA-B*51:01 may be linked to higher risks of TEN.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Toxic epidermal necrolysis (TEN) is a severe adverse drug re-
action characterized by necrosis of the epidermis. Keratinocyte cell
death causes detachment of the skin and mucous membrane from
the dermal-epidermal junction.1 The incidence rate is 0.5e1.4 per
million per year and the average mortality rate is 25e50%.2e7 The
mean patient age is 42.6 years and the incidence increases with
age.2,3 SJS and TEN have become to be classiﬁed under a single
category, and the difference between them is the amount of
epidermal detachment.8 However, in this review, TEN speciﬁcally
will be discussed because of its exceptional high mortality, rarity
and intense symptoms compared to SJS. In a typical course of TEN,ogy, Nippon Medical School,
).
ety of Allergology.
rgology. Production and hosting by Elsethe ﬁrst symptom is a ﬂu-like prodrome.9 Fever, malaise, and
pharyngitis may occur before the onset of mucocutaneous symp-
toms. Clinically, atypical targetoid macules appear on the skin.
These macules coalesce to form ﬂaccid blisters that slough off as
areas of epidermal necrosis (Fig. 1).1 Drugs, especially antibacterial
and antiepileptic drugs, are the most common cause. Speciﬁc hu-
man leukocyte antigen (HLA) alleles are high-risk factors as well.
HLA-B*15:02 in Asians being administered carbamazepine and
HLA-B*58:01 in people of all ethnicities being administered allo-
purinol have been reported to be high-risk factors for TEN.1 Rapid
diagnosis, discontinuation of the causative drug, and initiation of
supportive treatment are essential for better prognosis and
improvement of sequelae. Till now, systemic corticosteroids and
intravenous immunoglobulins (IVIg) have been used as the most
common active interventions; however, no gold standard has been
established.10 In Japan, as in the rest of the world, TEN is an
important disease. In this review, the situation of TEN in Japan at
the present will be discussed.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Patient of toxic epidermal necrolysis with epidermal sloughing showing bare
dermis. Coalescing violaceous macules can also be seen. There is widespread
involvement of trunk and extremities. Erosions with hemorrahagic crusts on lips can
also be seen.
Table 1
Summary of the 2 studies of TEN patients in Japan by Yamane et al.15,16
Number of patients 65 35
Year 2000e2006 2000e2013
Background of patients From articles of
medical journals, review
2 university hospitals,
case series
Male/female 31/34 17/18
Mean age 45.7 56.6
Most common
causative drug
Cephalosporin Antibiotics
Time until symptoms 2 weeks Average of 11.7 days
Range of skin
detachment
10e70% (Average 49.6%) 10e100% (Average 44.7%)
Most common
organ involvement
Hepatitis Hepatitis
Sepsis patients 7 6
Ocular complications 6 17
Mortality rate 6.20% 14.30%
TEN, toxic epidermal necrolysis.
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In Japan, TEN is characterized by an epidermal necrolysis greater
than 10% of the BSA. Although it is recognized that TEN can occur
following SJS, unlike in the rest of the world, there is no SJS/TEN
overlap, where epidermal necrolysis occurs in 10e30% of the BSA.11
Because it is a fatal disease, the Japanese Research Committee on
severe adverse reaction has created a diagnostic criteria and
treatment guideline to provide a speedy and accurate diagnosis and
effective treatment. A scoring system different from SCORTEN,
which is typically used worldwide has also been created to deter-
mine the severity of the condition. Besides total epidermal necrosis,
area and severity of mucosal lesions, percentage of blisters or
erosions, systemic symptoms (fever, respiratory failure, and liver
impairment) are included.12
Support to TEN patients
Japan has a unique relief system for patients suffering from
severe adverse drug reactions, and it was put in place in 1980.
When a Japanese patient who was administered a medication for
a reasonable licensed cause suffers from a severe drug reaction
that requires treatment by admission or results in severe sequelae
or death, the government ﬁnancially supports the patient or his/
her family for the treatment. This relief system also serves as a
useful means of accumulating data on TEN in Japan for further
analysis.13Incidence rate, causes, and common symptoms
For 2005e2007, the incidence rate of TEN in Japan was
0.28e0.52 per million per year.14 A retrospective study of 65 TEN
cases in Japan between 2000 and 2006 through published medical
journals, and another retrospective study of 35 TEN cases in 2
university hospitals in Japan between 2000 and 2013 provides the
following insights (Table 1).15,16 As per the Japanese guideline, pa-
tients with over 10% skin detachment, mucous membrane erosions,
and skin lesions were diagnosed with TEN. SJS/TEN overlap cases
were also considered to have TEN. The skin lesions were macules,
atypical target-like lesions, bullae, or erosions. In the former study,
31 patients were men and 34 women, and the mean patient age
was 45.7 years. All cases were caused by drugs, such as NSAIDs,
antibiotics, and anticonvulsants. Cephalosporinwas found to be the
most common causative antibiotic with 10 cases, and carbamaze-
pine the most common anticonvulsant with 8 cases. Patients
developed symptoms within 2 weeks. The range of skin detach-
ment was 10e70%, while the mean was 49.6%. Additional symp-
toms involving other organs, especially the liver and kidney, and
the respiratory system were common in many patients. Hepatitis
was the most common form of organ involvement, noted in 41
cases. Elevation of serum alanine aminotransferase level was the
most common blood test abnormality, observed in 33 cases (100 IU/
le1000 IU/l). 7 cases of sepsis were also reported; in patients with
SJS, only 1 case of sepsis occurred. Ocular complications were seen
in 6 cases.15 In the latter study, 17 patients were men and 18
women, and the mean patient age was 56.6 years. All cases were
caused by drugs, such as NSAIDs, cold medicines, antibiotics, and
anticonvulsants. Out of the cases where the causative drug was
determined, antibiotics were the most common with 7 cases. The
average interval until patients developed symptoms was 11.7 days.
The range of skin detachment was 10e100% of BSA, while the mean
was 44.7%. Additional symptoms involving other organs, especially
the liver and kidney, and the gastrointestinal systemwere common
in many patients. Hepatitis was the most common form of organ
involvement, noted in 15 cases. 6 cases of sepsis were also reported;
in patients with SJS, only 1 case of sepsis occurred. Keratocon-
junctivitis including conjunctival injection and erosions, and
pseudomembranes were seen in 17 cases. Labial and oral erosions
were observed in 19 cases. Genital problems, found mainly by pain
during urination, were observed in 17 cases of TEN.16
Mortality rate
Ranging from 6.2% to 32%, the most recent reported mortality
rate for TEN was 14.3% (2000e2013).13,15e17 The most recent
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21.6% (1981e1997), and this decrease may be due to the
improvement in diagnosis and treatment.17 Especially treatment
options have increased, including steroid pulse therapy, rarely
administered before 2000, plasmapheresis which became
admitted coverage by health insurance in 2006, and high dose
intravenous immunoglobulin (IVIg) which became admitted by
health insurance in 2014.15,16 In the retrospective study of 35 TEN
cases in 2 university hospitals in Japan between 2000 and 2013,
when comparing the mortality rate before and after plasmaphe-
resis eligibility, there was a remarkable decrease from 23.5%
(2000e2006) to 5.6% (2007e2013). Although steroid pulse ther-
apy and the combination of IVIg therapy (<2 g/kg) with cortico-
steroid therapy were the mainstream until 2006, the frequency of
cases treated with the combination of plasmapheresis and
corticosteroid therapy increased remarkably after 2007, making it
the most common treatment.16 Common points in deceased pa-
tients in reports where details were provided, were that the
mean age was over 50 years old, the majority women, majority
treated with corticosteroids alone, and that majority had
sepsis.15,16
Genetic susceptibility
There are speciﬁc HLA alleles that are associated with a high-
risk for TEN, and especially for the Japanese (Table 2). HLA-B*15:02
in Asians administered with carbamazepine and HLA-B*58:01 in
patients of all ethnicities administered with allopurinol are at high-
risk for SJS/TEN.6,14,18e25 The association of 2 of the most commonly
known HLAs, HLA-B*15:02 and HLA-B*58:01, with TEN is different
for the Japanese population. HLA-B*15:02 is not found in Japanese
patients with TEN, but a similar HLA, HLA-B*15:11, is. This HLA is
associated with TEN patients who were administered carbamaze-
pine, and can be relatively commonly found in Japanese
patients.21e23 The odds ratio (OR) for HLA-B*15:11 in Japanese
patients with carbamazepine-induced TEN was 9.76 (95% CI,
2.01e47.5). It has been suggested that some subfamilies of serotype
HLA-B75 are involved in the onset of carbamazepine-induced SJS/
TEN.22 HLA-B*58:01 is a more global biomarker for TEN, as it is
found in all patients regardless of ethnicity, including the Japa-
nese.19,20 In a caseecontrol study of patients with allopurinol-
induced adverse drug reactions (erythema exudavitum multi-
forme and SJS), 7 patients from Shimane University Hospital were
selected between 2010 and 2012. The OR for HLA-B*58:01 was the
highest at 65.6 (95% CI, 2.9e1497.0). None of the allopurinol-
tolerated control patients had HLA-B*58:01.23 In a multicenter
study where HLA-B genotyping was performed on 58 Japanese SJS/
TEN patients between July 2006 and April 2008, no HLA-B*15:02
carriers and 5 HLA-B*58:01 carriers were found. Four of the 5
HLA-B*58:01 carriers had allopurinol-induced SJS/TEN. The allele
frequency was high when compared to that in the Japanese pop-
ulation (OR, 40.83, p < 0.0001).25Table 2
HLA types and association with Japanese TEN patients.
HLA Association with Japanese TEN patients
HLA-A*02:06 Found, related with ocular complications
HLA-A*02:07 Found (zonisamide)
HLA-A*31:01 Found (carbamazepine)
HLA-A*51:01 Found (phenobarbital)
HLA-B*15:02 Not found
HLA-B*15:11 Found (carbamazepine)
HLA-B*58:01 Found (allopurinol)
HLA, human leukocyte antigen; TEN, toxic epidermal necrolysis.HLA-A*02:06 has been found in Japanese TEN patients, and is
especially related with ocular complications. In the same case-
econtrol study, HLA-A*11:01 was found to suppress ocular com-
plications. The OR for HLA-A*02:06 was 5.1 (p < 0.0005). HLA-
A*02:06 is less commonly found in Caucasians and Han Chi-
nese.24 Another HLA found in the Japanese that could increase the
risk of TEN is HLA-A*31:01. In a study conducted in 2011, the HLA-
A*31:01 allele was found in 37 of 61 (60.7%) patients with
carbamazepine-induced adverse drug reactions, compared with 47
of 376 (12.5%) carbamazepine-tolerant patients. The OR for HLA-
A*31:01 was 10.8 (95% CI, 5.9e19.6). Combining the results of a
replication study, the association of HLA-A*31:01 with SJS/TEN
patients in a subgroup analysis had an OR of 33.9.14 In the case of
Japanese patients, allopurinol and carbamazepine should be pre-
scribed with caution. Biomarkers for SJS/TEN caused by phenytoin,
zonisamide, and phenobarbital have been investigated in Japan,
and both HLA-A*02:07 and HLA-B*51:01 may be potential con-
tenders. In a retrospective caseecontrol study, HLA-A*02:07 was
found to be associated with zonisamide-induced SJS/TEN
(p¼ 0.0176), and HLA-B*51:01with phenobarbital-induced SJS/TEN
(p ¼ 0.0042). HLA-B*51:01 was marginally associated with
phenytoin-induced SJS/TEN as well. Phenobarbital and phenytoin
have similar chemical structures, and are very different from car-
bamazepine. This similaritymay be the reason for the association of
HLA-B*51:01 to both drugs.21
Treatment
No major differences exist between TEN management in Japan
and the world. Age and gender distribution, causative drugs, and
clinical symptoms in Japan are similar to those reported else-
where.15 However, the most recent mortality rate in Japan is lower
than that reported elsewhere.5e7,16 A systematic review published
in 2015 reported the absence of a globally accepted gold standard
for TEN treatment.26 Currently in the UK and US, no active in-
terventions are recommended. In all studies on TEN, except for the
randomized control trial of thalidomide by Wolkenstein that led to
the discontinuation of thalidomide treatment in 1998, variations in
treatment make interpreting the data difﬁcult.
The Japanese guideline recommends systematic steroids, IVIg,
and plasmapheresis as the 3 ﬁrst-line treatments of choice. Starting
from mPSL administered at 0.5e2 mg/kg/day, clinicians are rec-
ommended to refrain from blindly increasing the amount and to
consider pulse therapy in the absence of improvement. Ocular
symptoms, bullae or rapidly spreading detachment, and respiratory
symptoms are signs for initiating pulse therapy. For pulse therapy,
mPSL at 500e1000 mg/day for 3 days is recommended. The second
choice of treatment after steroids is both IVIg and plasmapheresis.
Either can be used, and oftenwhen either is not effective, the other
treatment is considered. The guideline recommends a dose of
5e20 g/day for 3e5 days.12 The amount of IVIg used in Japan is not
always more than 2 g/kg, which is considered as an effective
amount in reports from other parts of the world.16,27 The use of IVIg
at 0.4 g/kg/day for 5 days may have increased after 2014 when it
was admitted coverage by health insurance. Before 2014, ﬁnancial
reasons probably decreased its use. In Japan, usually IVIg is used in
combination often with corticosteroid, whereas in the rest of the
world, most treatments include monotherapy. The use of plasma-
pheresis in TEN patients is licensed in Japan since 2006.12 There
have been several successful reports of treatment in Japan
(Table 3).28e31
Systematic corticosteroids have been historically the ﬁrst choice
systematic treatment for TEN, with the ﬁrst use reported in 1976.32
For systemic corticosteroids, increased risks of gastrointestinal
problems and infection leading to increased mortality are the
Table 3
Successful treatment reports of TEN in Japan.28e31
Author Year of
study
Type of study Treatment Details of treatment Number of
patients
Outcome
Araki et al.28 2009 Case series Steroid pulse
therapy
Methylprednisolone 500 or
1000 mg/day 3e4 days
5 0/5 mortality
Hirahara et al.29 2013 Case series Steroid pulse
therapy
Methylprednisolone
1000 mg/day 3 days
þ oral prednisolone
(0.8e1 mg/kg/day)
± methylprednisolone
500 mg/day 2 days
8 0/8 mortality
Aihara et al.30 2012 Case series IVIg IVIg 400 mg/kg/day 5 days
as an additional therapy to
systemic steroids (20 mg/day
of prednisolone equivalent)
administrated 2 days;
1 patient: Maximum 30e60 mg/day
prednisolone or prednisolone equivalent
2 patients: Methylprednisolone
1000 mg/day 3 days
3 0/3 mortality
Yamada et al.31 2008 Review Plasmapheresis Simple plasma exchange or
Double ﬁltration plasmapheresis
44 patients
Other type 3 patients
47 11/47 mortality
TEN, toxic epidermal necrolysis; IVIg, intravenous immunoglobulin.
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costeroids in the initial stage of SJS/TEN, including pulse therapy is
suggested to be beneﬁcial from articles set in Japan.28,29 The efﬁ-
cacy of steroid pulse therapy in Japan has been reported. In a pro-
spective case series by Araki et al., 5 patients with SJS or TEN with
ocular complications at the acute stage were given steroid pulse
therapy of methylprednisolone 500 or 1000 mg/day for 3e4 days,
within 4 days from disease onset. Ocular complications such as
corneal or conjunctival epithelial defects, and pseudomembranous
conjunctivitis present in all cases in the beginning, improved in all
cases.28 In another study by Hirahara et al., 8 patients were given
1000 mg/day of methylprednisolone for 3 days. This was followed
by oral prednisolone (0.8e1 mg/kg/day), which was tapered grad-
ually. If high grade fever persisted or reduction in BSA was not
observed after the last dose of pulse therapy, a course of half-dose
methylprednisolone pulse therapy (500 mg/day for 2 consecutive
days) was administered. No patients died during in the 3 months
after, whereas predicted mortality was 1.6 deaths according to
SCORTEN.29
IVIg has gained popularity as the ﬁrst choice systematic treat-
ment for TEN, since its advocation in 1998.7 According to a sys-
tematic review published in 2012, IVIg alone is not beneﬁcial; thus,
its usability is limited.35 However as a part of a combination ther-
apy, its beneﬁcial effect has been suggested in an article in Japan.30
In a study by Aihara et al. in 2015, the efﬁcacy of IVIg was evaluated.
IVIg was administrated for 5 days consecutively, in an open-label,
multicenter, single-arm study in patients with SJS or TEN. IVIg
(400 mg/kg/day) administrated for 5 days consecutively was per-
formed as an additional therapy to systemic steroids in adult pa-
tients with SJS or TEN. IVIg was started from 3 to 23 days after the
onset of skin lesions. Efﬁcacy on day 7 was evaluated. 8 patients,
including 3TEN patients who did not respond sufﬁciently to sys-
temic steroids were treated. Although because the degree of
improvement did not fulﬁll the response criteria (SCORTEN
reduction 6 on day 7) and 1 TEN patient was considered a non-
responder, all the patients improved their symptoms, and sur-
vived. The efﬁcacy on day 7 was 87.5% (7/8 patients). In the 7 SJS or
TEN patients that responded to IVIg, epidermal detachment
reduced from 9.4% to 0.3% when comparing day 1 and day 7 aftersymptoms appeared. Erythema reduced from 51.4% to 17.1%. Details
of only one successful TEN patient were described in the study, and
in that case, steroids were given one day after symptoms, and IVIg
was given 9 days after symptoms, and 8 days after steroids. The
symptoms ceased after IVIg, and re-epithelialization started 2 days
after IVIg.30 The combination of IVIg and corticosteroid, has been
thought to reduce mortality rate from before.36 The timing of IVIg
to be beneﬁcial has been suggested in other studies, to be before the
epidermal detachment occurs in TEN, and earlier the better. This
detachment is usually 4e6 days after the initial skin symptoms.37,38
In the study by Aihara et al., the timing of IVIg for the other 1
successful TEN case was 9 days after cutaneous symptoms, while
the non-responder was 23 days. The timing could have contributed
to the beneﬁcial effect.30
Plasmapheresis has been reported to be effective, through case
reports and a literature review especially in Japan.31,39e44 Whether
simple plasma exchange or double ﬁltration plasmapheresis is
more beneﬁcial, remains to be known. In a literature review of TEN
cases treated with plasmapheresis in Japan, 47 patients were
treated until 2006. The rate of effectiveness was 80.9% and the
mortality rate was 23.4% with 11 deaths. Thirty six of the cases had
been used corticosteroids prior to plasmapheresis but had no
effect.31
In the case of cyclosporine, an entire month is required to ach-
ieve its full therapeutic beneﬁt and this is not feasible for an acute
disease like TEN.45 In case of anti-TNF therapy, except thalidomide,
which is a contraindicated TEN treatment, etanercept and inﬂix-
imab seem beneﬁcial. N-acetylcysteine seems to be beneﬁcial as
well, but it has only been used in case reports thus far.46e49 There
are no case reports of TEN patients treated with cyclosporine, anti-
TNF therapy or N-acetylcysteine in Japan.
The lower mortality rate in Japan could be partly because TEN is
deﬁned at 10% epidermal detachment and treatment is initiated at
earlier stages. In the literature, pulse therapy is reported to be
beneﬁcial and its usage may improve the mortality rate in Japan.
Moreover, the TEN treatment guidelines in Japan are efﬁcient, with
supportive therapy that overcomes the drawbacks of active in-
terventions, especially corticosteroids.12 Rapid diagnosis, discon-
tinuation of the drug, and hospital admission are vital to TEN
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should be taken into consideration while prescribing especially
high-risk drugs. The deﬁnition describing TEN as BSA detachment
>10% is more effective as it prompts treatment for TEN rather than
for SJS/TEN overlap. However, although the Japanese deﬁnition,
diagnostic criteria, scoring system, and treatment guidelines are
helpful in managing daily clinical situations, they make it difﬁcult
to compare cases with those reported from other parts of theworld,
which are usually diagnosed on the basis of the criteria described in
the Bastuji study. As for the treatment, although only supportive
therapy is considered to be the best treatment at present in other
countries, active interventions of corticosteroids, IVIg, and plas-
mapheresis are employed commonly in Japan, and has been re-
ported to be beneﬁtical.28e31
The recent topic in management of SJS/TEN is that drug-induced
hypersensitivity syndrome (DIHS) and SJS/TEN overlap often results
in critical outcomes.50,51 DIHS is characterized by fever, rash, he-
patic dysfunction, hematological abnormalities and lymphade-
nopathy.50 DIHS cases associated with skin manifestations similar
to SJS/TEN have been reported. All or most of the criteria of DIHS
was fulﬁlled, but also mucosal involvement and epidermal
detachment was seen. DIHS is diagnosed based on its characteristic
clinical course, multiple organ involvement, and detection of
herpesvirus reactivation. The skin manifestations of DIHS include
maculopapular rash, erythema multiforme, exfoliative dermatitis,
acute generalized exanthematous pustular dermatosis-like erup-
tion or erythroderma and can have mucosal involvement. There is
no speciﬁc mucocutaneous symptom for DIHS. On the other hand
SJS/TEN is diagnosed by characteristic mucocutaneous symptoms.
Whether there is organ involvement does not matter. Therefore, a
case diagnosed as SJS or TEN from its mucocutaneous symptoms,
can also be diagnosed as DIHS from its clinical course and positive
viral reactivation (Table 4).10,51 Time of onset after the initiation of
the causative drug does differ between DIHS and SJS/TEN. DIHS has
a later onset of 2e6 weeks in 80% of the cases, most commonly at
4e5 weeks, while SJS/TEN has an early onset of within 3 weeks for
67% of cases. However, in the overlapping cases, the onset is 4e5
weeks after the start of the drug, just between the most common
timing of SJS/TEN and DIHS. The overlapping cases were all caused
by anticonvulsants.51
In another study by Teraki et al., 8 patients diagnosed with SJS/
TEN due to anticonvulsants were examined, and a similarity with
DIHS was seen. Seven of the 8 patients developed symptoms >3
weeks after starting anticonvulsants. Hepatic dysfunction was
present in 6 patients, leukocytosis and/or eosinophilia in 7 patients,
reactivation of HHV-6 in 1 of the 4 patients.50Table 4
Comparison of SJS/TEN, DIHS and overlap of SJS/TEN and DIHS.
SJS/TEN DIHS Overlap of SJS/TEN
and DIHS
Diagnosis Skin and
mucosal
manifestation
Skin and mucosal
manifestation
Clinical course
Clinical course
Organ involvement
Organ involvement
Detection of
herpesvirus
reactivation Detection of
herpesvirus
reactivation
Onset 67% of cases
0e3 weeks
80% of cases
2e6 weeks
4e5 weeks
Most frequently
at 4e5 weeks
Most common
causative drugs
Anticonvulsant
and antibiotics
Anticonvulsants Anticonvulsants
DIHS, drug-induced hypersensitivity syndrome; SJS/TEN, Stevens-Johnson syn-
drome/toxic epidermal necrolysis.Eye care
Consulting the ophthalmologist is essential to TEN. When there
is ocular involvement, the combination of aggressive lubrication,
topical antibiotics, topical corticosteroids and lysis of adhesions
with a glass rod is necessary. However, this has had only a modest
effect on long-term ocular complications. Recently, amniotic
membranes transplant has been shown to be effective in preserving
visual acuity and an intact ocular surface.52,53 A physical barrier
between the inﬂamed and denuded mucosal surfaces may mini-
mize the formation of adhesions, and may be anti-inﬂammatory
and antiﬁbrotic.53
Conclusion
TEN is an important disease in Japan and the rest of the world.
Although there are differences between diagnosis and recom-
mended treatments, reducing the mortality rate has been the goal
worldwide. HLA-A*02:06, HLA-A*02:07, HLA-A*31:01, and HLA-
B*51:01 may be high-risk factors for TEN in Japanese individuals,
and in the future, routine checks should be considered. Further
research into the pathogenesis of TEN is warranted, and new
ﬁndings may contribute toward a more effective active
intervention.
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